title: Serotonin2c receptor constitutive activity: in vivo direct and indirect evidence and functional significance.
abstract: Serotonin2c (5-HT2c) receptors are widely expressed in the central nervous system where they play a pivotal role in the regulation of neuronal network excitability. Along with this fundamental physiological function, 5-HT2c receptors are thought to be implicated in the pathophysiology of several neuropsychiatric disorders and have become a major pharmacological target for the development of improved treatments of these disorders. In the past decade, many studies have focused on the constitutive activity of 5-HT2c receptors and the therapeutic potential of drugs acting as inverse agonists. Although the constitutive activity of the 5-HT2c receptor has been clearly described in vitro, the transposition of this concept to living animals is often difficult to ascertain. Nevertheless, cumulating evidence has demonstrated the functional relevance of such property in regulating physiological systems in vivo both at the level of the central and peripheral nervous systems. The present review provides an update of the growing number of studies that show, by means of pharmacological tools, the participation of the constitutive activity of 5-HT2c receptors in the control of various biochemical and behavioural functions in vivo and emphasizes the functional organization of this constitutive control together with the phasic and tonic (involving the spontaneous release of 5-HT) modalities of the 5-HT2c receptor in the brain.
authors: Institut des Maladies Neurodégénératives, UMR CNRS 5293, Université Bordeaux 2, 146 rue Léo Saignât, 33076 Bordeaux Cedex, France. deurwaer@u-bordeaux2.fr.
authors: Sylvia
authors: S
authors: Navailles
authors: Mélanie
authors: M
authors: Lagière
authors: Martin
authors: M
authors: Guthrie
authors: Philippe
authors: P
authors: De Deurwaerdère
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects; D016762:Genes, fos; D019416:Head Movements / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007175:Impulsive Behavior; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009415:Nerve Net / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D051381:Rats; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects / Q000502:physiology*; D059326:Serotonergic Neurons / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D058826:Serotonin 5-HT2 Receptor Agonists / Q000494:pharmacology; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology; D013045:Species Specificity; D013119:Spinal Cord Injuries / Q000503:physiopathology
chemical_list: D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D012701:Serotonin; D004298:Dopamine